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32P-Postlabeling Assay for Carcinogen-DNA
Adducts: Nuclease P1-Mediated
Enhancement of Its Sensitivity and
Applications
by M. Vijayaraj Reddy*tand Kurt Randerath*
Exceedingly sensitive assays are required for the detection of DNA adducts formed in humans exposed
to low levels of environmental genotoxicants and therapeutic drugs. A 3P-postlabeling procedure for
detection and quantitation of aromatic carcinogen-DNA lesions with a sensitivity limit of 1 adduct in 107
to 108 nucleotides has been described previously. In the standard procedure, DNA is enzymatically digested
to 3'-phosphorylated normal and adducted mononucleotides, which are 32P-labeled at their 5'-hydroxyl
groups by T4 polynucleotide kinase-catalyzed [32P]phosphate transfer from [y-32P]ATP. 3P-labeled deriv-
atives are resolved by TLC, detected by autoradiography, and quantitated by counting. This assay has
beenrecently utilizedforthedetermination andpartial characterization ofDNAadductsformed insomatic
and reproductive tissues ofrats given the clinically used anticancer drug, mitomycin C. The drug exhibits
similar levels of covalent binding to DNA in most tissues. Further studies have revealed that adducted
nucleotides are primarily guanine derivatives that are resistant to 3'-dephosphorylation by Penicillium
citrinum nuclease Pl. The latter observation has been utilized to enhance the 32P-assay's sensitivity to 1
adduct in 1010 nucleotides for a 10-R±g DNA sample by postincubation of DNA digests with nuclease P1
before 32P-labeling. The enzymedephosphorylates the normal nucleotides but not most aromatic andbulky
nonaromatic adducts, so that only the latter serve as substrates forthe kinase-catalyzed labelingreaction.
The new assay has also shown utility in the analysis of very low levels of age- and tissue-related DNA
modifications, which might arisefromdietary orendogenouscompounds, inuntreatedratsandin humans.
Introduction
It is well documented that naturally occurring and
synthetic chemicals play a role in the etiology ofhuman
cancer (1). In experimental animals and cultured human
cells, the majority, but not all, of mutagenic and car-
cinogenic compounds are converted viachemical ormet-
abolic activation to electrophiles; these reactive inter-
mediates interact with DNA, RNA, and proteins,
resultingintheformation ofcovalentadducts (2,3). Sev-
eral lines of evidence suggest that DNA is the critical
target molecule in the initiation ofmultistage chemical
carcinogenesis. First, most carcinogens are mutagens,
i.e., they react with DNA (4). Second, the carcinogen-
icity of aseries ofpolycyclic aromatic hydrocarbons cor-
relates with their binding to DNA, rather than to RNA
and protein (5). Third, defects in DNA repair such as
in xeroderma pigmentosum predispose to cancer devel-
opment (6). Last, in vitro modification of the ras pro-
tooncogene with the ultimate carcinogens of ben-
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zo[a]pyrene or2-acetylaminofluorenegenerates atrans-
forming oncogene when introduced into NIH 3T3 cells
(7). Methods for the detection of DNA alterations or
damage arethusessentialfortheidentification ofpoten-
tial carcinogens/mutagens in the human environment,
and their application assists in the prevention or min-
imization of exposures to such compounds.
Several powerful short-term in vitro assays employ-
ing bacteria, lower eukaryotes, or mammalian cells in
culturehavebeendevelopedtodetectgenotoxicactivity
of chemicals (8,9). Since these systems are unable to
convert carcinogens to electrophilic species, exogenous
sources of metabolic enzymes are added. However,
these in vitro assays do not completely mimic the in
vivo situation, which entails complex biological inter-
actions such as absorption, distribution, activation,
detoxification, and repair ofDNA damage. This makes
it difficult to extrapolate results ofin vitro tests to the
situation in whole animals and humans. Therefore, a
need is apparent for the development ofin vivo assays,
preferablyassaysthatarecapableofdirectlymeasuring
DNA damage. Radioactive carcinogens or antibodies
specific to known adducts have been utilized in such
studies (10,11). Neitherapproach can bereadilyappliedREDDY AND RANDERATH
to the large number ofchemicals present in the human
environment; hence, alternative techniques have been
sought. A general and sensitive approach for the mea-
surement of DNA lesions formed with nonradioactive
carcinogens has been described (12-15), in which nor-
mal and adducted nucleotides, generated by nuclease
digests ofDNA modified in vivo or in vitro with a com-
pound ofinterest, are labeled with 32P and detected and
quantitated after TLC. The 32P-approach has been
applied to approximately 100test chemicals, comprising
arylamines and derivatives, azo compounds, nitroaro-
matics, polycyclic aromatic hydrocarbons, and methy-
lating agents (14), as well as mycotoxins (16), hetero-
cyclic polycyclic aromatics (17), alkenylbenzene deriv-
atives (18,19), and estrogens (20). With each carcinogen
tested, 32P-labeled DNAadducts werereadilydetected,
showing the potential use of the 32P-assay as a short-
term in vivo test for screening genotoxic chemicals. In
this review, we describe results obtained by adapting
the method to mitomycin C (MMC) (21), aclinically used
anticancer drug produced by Streptomyces caespitosus
(22). In addition, we discuss a minor modification ofthe
standard procedure, which enhances the method's sen-
sitivity about 1000-fold, i.e., to 1 adduct in approxi-
mately 1010 DNA nucleotides (23), and applications of
this approach (24-26).
Materials and Methods
The sources of biochemical, chromatographic, and
autoradiographic materials have been documented pre-
viously (12-15). [_y-32P]ATP and polyethyleneimine
(PE )-cellulose sheets were prepared in the laboratory
(13,27). For analysis ofthe tissue distribution ofMMC-
DNA adducts, Fischer 344 male and female rats
(approximately 150 g) were given IP 9 mg/kg MMC in
3.6 mL of0.9% NaCl; control rats received 0.9% NaCl.
Tissues were collected 24 hr later, and DNA was iso-
lated by a modified digestion and extraction procedure
(21). DNA adducted with 7,12-dimethylbenz-
[a]anthracene (DMBA) [relative adduct labeling (RAL)
= 34.4 x 10-7] was isolated from the skin of mice 24
hr after topical application of 1.2 ,umole DMBA. BP-
DNA (RAL = 10.8 x 10-7] and ABP-DNA (RAL =
105.8 x 10-7) were extracted from maternal intestine
and maternal liver, respectively, 24 hr after per os
administration of200 ,umole/kg benzo[a]pyrene (BP) or
800 ,umole/kg 4-aminobiphenyl (ABP) to pregnant ICR
mice on day 18 of gestation (28). DBC-DNA (RAL =
561.1 x 10-7) was obtained fromfemale BALB/c mouse
liver 24 hr after topical application to the skin of 80
,umole/kg DBC (M. E. Schurdak and K. Randerath, in
preparation).
3 P-postlabeling analysis of DNA adducts was per-
formed as described previously (12-15,21,23,29). DNA
wasenzymatically digestedto3'-mononucleotides(dNp)
(30). In the standard assay, 0.17 ,ug of DNA digest (50
,uM dNp) was 32P-labeled with 60 ,uM [y-32P]ATP (250-
600 Ci/mmole) (21,23), and any unused [y-32P]ATP was
converted to 32Pi by digestion with apyrase. In the
adduct intensification procedure, 2 ,ug of DNA digest
(400 ,uM dNp) was 32P-labeled with 1.7 ,uM carrier-free
[y-32P]ATP (approximately 4000 Ci/mmole) (21,29). In
the nuclease Pl-enhanced version ofthe assay, 10 ,g of
DNA digest was treated with nuclease P1 (6 ,ug) for 40
mintoremovenormalnucleotides, then32P-labeled with
excess carrier-free [_y-32P]ATP (23). Purification and
separation of32P-labeled adducted nucleotides was per-
formed by PEI-cellulose anion-exchange TLC in the
case ofadducts fromBP, DMBA, DBC, and4-ABP (21),
whereas for MMC adducts, a combination of octadecyl
silane reversed-phase TLC and PEI-cellulose TLC was
employed (21). After detection by screen-enhanced
autoradiography, adduct spots were cut out for quan-
titation from replicate maps and counted by Cerenkov
assay. Appropriate blank areas of the chromatograms
were also assayed and theircountrates subtracted from
sample count rates. Adduct levels were calculated as
relative adduct labeling (RAL), which is the ratio of
count rates of adducted nucleotides to count rates of
total (adduct plus normal) nucleotides. The latter were
evaluated by TLC of an aliquot of the labeled solution
(21). In the intensification procedure, apparent RAL
values (<RAL>) were dividedbyadductintensification
factors to obtain actual RAL values (21,29). After
nuclease P1 treatment, which removes normal nucleo-
tides prior to 32P-labeling, the specific activity of [y-
32P]ATP was determined by 32P-labeling of dAp and
utilized for RAL calculations (23). A value of RAL x
107 corresponds to 1 adduct in 107 nucleotides or 0.3
pmole of adduct/mg DNA, provided that adducts are
labeled and recovered quantitatively. Using DNA mod-
ified in vivo with [3H]1'-hRydroxy-2',3'-dehydroestra-
gole (31) or in vitro with [ H]N-hydroxy-2-aminofluo-
rene or [3H]ben- zo[a]pyrene diol epoxide I (13), the
levels ofadducts determined by 32P-postlabeling analy-
sis have been shown to be 50 to 80% ofthose obtained
by analysis ofthe tritiated adducts.
Results and Discussion
32P-Analysis of MMC-DNA Adducts
MMC, a potent antitumor antibiotic, is a drug used
clinically for the treatment ofcancers ofstomach, pan-
creas, lung, cervix, bladder, and breast (22). It is car-
cinogenic to rats and generates mutations in sperma-
togonia of male mice. The compound produces sister
chromatid exchanges in bone marrow and testis ofrats
and mice and in lymphocytes of humans following in
vivo treatments (22,32). In in vitro, chemically or enzy-
matically reduced MMC has been shown to react with
DNA, formingmonofunctional and bifunctional adducts
in ratios, which vary depending on the reductive con-
ditions (33,34); however, little information is available
to date on in vivo adduction of tissue DNAs by MMC
(23), probably because of unavailability of the drug in
radiolabeled form. Using the 32P-postlabeling assay
(Fig. 1), we have studied the formation ofMMC-DNA
adducts in several somatic and reproductive tissues of
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Carcinogen - adducted DNA
Micrococcal endonuclease
+ spleen exonuclease
Ap + Gp + Tp + Cp + m5Cp + Xp + yp..
(Normal nucleotides) (Adducts)
132P] phosphate transfer:
[y 32p] ATP + T4 polynucleotide kinase
pAp+ pGp+ pTp+pCp+pm5Cp+pXp+pYp+ .. .
Removal of normal nucleotides:
PEI-cellulose or reversed-phase TLC
or reversed-phase HPLC
pXp + pYp + .. .
Separation and detection of adducts:
i) PEI-cellulose TLC
(ii) autoradiography
Maps of 32P-labeled carcinogen-DNA adducts
FIGURE 1. Th basic features of 32P-postlabeling assay for carcino-
gen-adducted DNA. The 32P-assay involves four steps: digestion
of DNA, 32P-labeling of the digestion products, removal of 32P-
labeled nonadduct components, and TLC mapping of the
[32P]adducts. Asterisks indicate the position ofthe 32P-label. Puri-
fication of adducted nucleotides derived from carcinogens having
two or more aromatic rings (e.g., BP, DMBA, DBC, and ABP) is
accomplished by PEI-cellulose TLC (13-15), while for adducts
carrying a single aromatic ring (e.g., alkenylbenzenes and ster-
igmatocystin) or a bulky nonaromatic ring (e.g., MMC), octadecyl
silane reversed-phase TLC is preferred (16,18,19,21).
rats at 24 hr after administration of 9 mg/kg of MMC.
32P-fingerprints of DNA adducts in some selected tis-
sues are shown in Figure 2. The map of bladder DNA
showed 10 extraspotsthat were absentfromthecontrol
DNA map (panel a). DNA adduct patterns were qual-
itatively similar in different tissues, except that in less
modified DNA samples (e.g., from brain and testis), not
all the adduct spots were detected. Since MMC-DNA
digests were 32P-labeled with [y-32P]ATP at a concen-
tration below that ofdNp to increase the sensitivity of
the 32P-assay (adduct-intensification procedure), P-
incorporation into adducts was corrected by intensifi-
cation factors (21) for RAL calculations. Figure 3 shows
RAL values of adduct 1 and of total 32P-labeled MMC
derivatives in DNA specimens isolated from 14 tissues
of female rats (from left to right), as well as from liver
and testis ofmale rats (the last two bars from the right)
at 24 hr after IP administration of a 9 mg/kg dose of
MMC. On average, adduct 1 comprised 71 (± 5%) of
the total. With the exception of brain, thymus, and
spleen, total adduct levels varied within a two-fold
range in 11 tissues in female rats, i.e., bladder, colon,
esophagus, heart, kidney, liver, lung, ovary, pancreas
small intestine, and stomach (9.6-21.9 adducts/10
nucleotides). TheubiquitousbindingofthedrugtoDNA
in tissues is consistent with the carcinogenic (35) and
the cytotoxic and necrogenic (36) effects ofthe drug in
multiple organs of rats. The exceptionallX low level of
DNA modification in brain (0.7 adduct/10 nucleotides)
was probably due to poor penetration by MMC of the
blood-brainbarrier. LiverDNAadductionwas32%low-
er in male compared with female rats. Ovarian DNA
was 5.3 times more highly modified than was testicular
DNA.
We have partially characterized the in vivo adducts
by cochromatography with [32P]adduct standards gen-
erated in vitro bythe reaction ofNaBH4-reduced MMC
with DNA and polydeoxyribonucleotides, followed by
32P-labeling (21). With rat liver DNA modified in vitro,
10 [32P]adduct spots were detected, which were chro-
matographically identical to those formed in vivo, dem-
onstrating that activation of MMC occurred via reduc-
tion. In vivo adducts 1 to 5 were guanine derivatives,
as they cochromatographed with adducts formed with
poly dG. MMC-poly dC gave two adducts comigrating
with in vivo adducts 7 and 9, while MMC-poly d(AT)
gave two adducts cochromatographing with in vivo
adducts 8 and 10.
While in vivo and in vitro MMC-DNAs showed two
main adducts and eight minor derivatives by 32P-analy-
sis, formation of only one major adduct (> 90%) and
two minor (2-5%) products has been reported with in
vitro-modified DNA on the basis of HPLC and NMR
analysis (33,34). The greater number of adducts seen
by the 32P-assay could be due to its higher sensitivity
or incomplete digestion of DNA giving oligonucleotide
adducts, such as those previously observed with ster-
igmatocystin-modified DNA (16). We have employed
nuclease P1 for the characterization of oligonucleotide
adducts. This enzyme cleaves 3'-phosphomonester and
3',5'-phosphodiester bonds ofpolynucleotides, yielding
5'-phosphorylated nucleotides. Following nuclease P1
treatment, oligonucleotide adducts of the structure
*pNpXp (16) should give *pN, pX, and Pi as the prod-
ucts, where * denotes the
_ P-label, N is normal nucleo-
tide, X is a MMC adduct, and Pi is inorganic phosphate.
The MMC-modified deoxyribonucleoside 3',5'-bisphos-
phate, *pXp, on the other hand, should give *pX and
Pi. When 3 P-labeled in vivo MMC adducts 1 to 4 were
isolated and digested with nuclease P1, neither *pN nor
*pX were formed, while, as expected, reference normal
nucleotides (*pNp) were hydrolyzed to *pN, showing
that adducted nucleotides were resistant to 3'-dephos-
phorylation by this enzyme. We asked if this property
ofthe enzyme could be utilized to enhance the sensitiv-
ity of the 32P-assay further. As detailed in the next
section, a 500- to 1000-fold increase in sensitivity ofthe
procedurecouldbeaccomplishedbyincludinganuclease
P1 treatment step prior to 32P-labeling (23).
Nuclease P1-Enhanced Version of
the 32P-Assay and Its Applications
Thisisaslightmodificationofthestandardprocedure,
entailing a 40-min incubation of 3'-nucleotides in the
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FIGURE 2. Autoradiograms of PEI-cellulose maps of 32P-labeled MMC-DNA adducts. Samples were (a) bladder DNA from untreated rats;
(b-h) DNAs from the indicated tissues of MMC-treated female rats; and (i) testicular DNA from male rats. Labeled DNA digests were
prepared according to the scheme shown in Fig. 1 under adduct intensification conditions. Adducted [32P]nucleotides were freed ofnormal
[32P]nucleotides by reversed-phase TLC at 4°C, contact-transferred and resolved by two-dimensional PEI-cellulose TLC (21,23), located
by screen-intensified autoradiography at -80°C for 6 hr. Faint spots (nos. 7-10), requiring longer exposure times (1-2 days), have been
circled. Spot 1' was a fraction of adduct 1 retained during chromatographic development (21).
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0 Total
15 U Adduct 1
10
5
tissue DNAs of female and male rats given MMC. Adduct spots
shown in Fig. 1 were cut from quadruplicate maps and counted.
Binding is expressed as RAL values, as outlined in "Materials and
Methods." Since the recoveryofadduct 1 was 47.5%, multiplication
of its RAL values by a factor of 2.11 yields actual RAL values
(21). Bars indicate mean SD.
Carcinogen-adducted DNA
| Micrococcal endonuclease
l + spleen exonuclease





(- 250 Ci/mmol) + kinase
*pNp + *pXp + *pYp + * -
Nuclease P1 procedure
(5ig DNA or more)
Dephosphorylation of Np:
Nuclease P1




*pXp + *pYp + . .
TLC
Autoradiography
Maps of 32P-Labeled adducts
FIGURE 4. Experimental strategy employed in standard and
nuclease P,-enhanced procedures for 32P-postlabeling analysis of
carcinogen-DNA adducts. Nuclease P1 dephosphorylates 3'-mon-
ophosphates ofnormal nucleotides, but not adducted nucleotides,
so that the latter are enriched prior to 32P-labeling. Np indicates
normal nucleotides (dGp, dAp, dCp, dm5Cp, and dTp). Xp, Yp
denote adducted deoxyribonucleotides. See legend of Fig. 1 for
additional details.
initial micrococcal endonuclease/spleen phosphodiester-
ase digests ofDNA with nuclease P1 (Fig. 4). Nuclease
P1 dephosphorylates normal, but not adducted, nucleo-
tides to nucleosides. Since nucleosides are not sub-
strates forpolynucleotide kinase, only adducted nucleo-
tides are32P-labeled inthesubsequentlabelingreaction.
The enzymatic removal of normal nucleotides enables
the specific labeling of adducts in up to 20 ,ug of DNA
with excess [_y-32P]ATP ofhigh specificactivity (approx-
imately 4000 Ci/mmole). The assay's sensitivity is
increased about 1000-fold compared with the standard
procedure, in which normal and adducted nucleotides
from 0.17 ,ug of DNA are simultaneously labeled with
approximately 250 Ci/mmole of [y-32P]ATP. The
enhancement is due to two factors: the labeling of
adducts derived from a larger amount ofDNA and the
use of[_y-32P]ATP ofhigh specific activity. The nuclease
P1 procedure was validated with respect to its appli-
cability to the measurement of DNA adducts formed
with structurally diverse carcinogens. As examples,
Figure 5 shows the 32P-adduct patterns of BP-DNA,
DMBA-DNA, DBC-DNAandABP-DNA, respectively,
analyzed bythe nuclease P1 procedure (panels a-d) and
under standard conditions (panels e-h). Adduct pat-
terns obtained by the two assays were qualitatively
similar, but large quantitative differences were
observed. Thiswasindicated by a50 to250 times short-
er film exposure for the upper row of autoradiograms
and the more sensitive detection ofweak spots. Count-
ing of adduct fractions shown in Figure 5, as well as
adducts of safrole and MMC (23), revealed that a total
of30 out of34 adducts were enhanced 300- to 1000-fold
in terms of 32P-incorporation. Recoveries were 50 to
100% after nuclease P1 treatment compared with the
standard assay. These results showed that most aro-
maticandbulkynonaromaticadducted nucleotideswere
virtually resistant to 3'-dephosphorylation by nuclease
P1. Recoveries oftwo ABP adducts (Fig. 5, nos. 1 and
4) were lower (4-7%), but the gain in sensitivity was
still30-to60-foldinrelationtostandardconditions. Two
minor adducts, i.e., an ABP derivative (Fig. 5, no. 3)
and a safrole derivative, showed properties similar to
normal nucleotides upon nuclease P1 treatment (23).
Thenuclease P1-enhanced versionofthe32P-assayhas
already shown utility in anumberofcases requiringthe
analysis of very low DNA adduct levels. First, using
this assay, we have detected the age- and tissue-depen-
dent formation of covalent DNA modifications (termed
I-compounds) in liver, kidney, lung, and heart of
untreated Sprague-Dawley rats of different ages (24).
This DNA modification could be due to environmental
(e.g., dietary) factors or endogenous DNA-reactive
metabolites (20) and may play a role in spontaneous
tumor induction or aging (24). Second, putative aro-
matic DNA derivatives, which may be related to I-com-
pounds seen in untreated rats, have also been observed
inplacenta (26), bone marrow (25), and peripheralblood
leukocytes (25) ofnonsmoking humans. Third, the new
assay has recently been applied to DNA samples from
placenta and white blood cells ofnonsmoking, pregnant
women who had a history of exposure to residential
wood smoke, i.e., a mixture known to contain carcino-
genic polycyclic aromatic hydrocarbons. No exposure-
related adducts were detected, showingthatresidential
wood smoke fails to induce levels ofcovalent DNA dam-
age comparable to cigarette smoke (26). Last, the
nuclease P1 version ofthe 32P-postlabeling assay is con-
siderably more sensitive for many aromatic, including
cigarette smoke-induced adducts, than the intensifica-
tion version of the assay previously employed for the
detection ofadducts in smokertissues [(37) and E. Ran-
derath and K. Randerath, unpublished results].
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Conclusions
In vivo formation ofcarcinogen-DNA adducts in var-
ious somatic and reproductive tissues of experimental
animals can be measured by a 32P-postlabeling assay,
as documented in this report with mitomycin C, a clin-
ically used drug. The 32P-assay is very sensitive, espe-
cially in combination with nuclease P1 enhancement,
which enables the detection and quantitation of most
aromatic and bulky nonaromatic adducts at frequencies
as low as 1 lesion per 1010 DNA nucleotides. In addition
to its already demonstrated utility for the detection of
DNAadductsinsmokers, thenewassaymaypotentially
be applicable to DNA adduct measurements in exper-
imental animals given single or mixed carcinogens at
low dose levels that correspond to human exposures.
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